Postprandial effects of the phosphodiesterase-5 (PDE-5) inhibitor tadalafil in type 2 diabetes patients: a randomised controlled trial

被引：0
作者：
Sjogren, L.
Olausson, J.
Strindberg, L.
Mobini, R.
Fogelstrand, P.
Hulten, L. Mattsson
Jansson, P. -A.
机构：
来源：
DIABETOLOGIA | 2014年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
116
引用
收藏
页码：S55 / S56
页数：2
相关论文
共 50 条
[41]   Transient global amnesia after intake of tadalafil, a PDE-5 inhibitor: a possible association? [J].
Schiefer, J ;
Sparing, R .
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2005, 17 (04) :383-384
[42]   Transient global amnesia after intake of tadalafil, a PDE-5 inhibitor: a possible association? [J].
J Schiefer ;
R Sparing .
International Journal of Impotence Research, 2005, 17 :383-384
[43]   Effect of Phosphodiesterase-5 (PDE-5) Inhibitors on Clinical Outcomes in Patients With Pulmonary Hypertension: A Meta-Analysis of Randomized Control Trials [J].
Karedath, Jithin ;
Dar, Hassaan ;
Ganipineni, Vijay Durga Pradeep ;
Gorle, Sri Anjali ;
Gaddipati, Sarvani ;
Bseiso, Anan ;
Pizzorno, Guiomarly ;
Shaik, Tanveer Ahamad .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (01)
[44]   Evaluation of arterial stiffness and cardiac function in patients with vascular erectile dysfunction: acute effects of phosphodiesterase-5 inhibitor tadalafil [J].
Ozdabakoglu, O. ;
Gullulu, S. ;
Sag, S. ;
Senturk, T. ;
Kilicarslan, H. ;
Tutuncu, A. ;
Kecebas, M. ;
Baran, I. ;
Aydinlar, A. .
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2017, 29 (03) :96-100
[45]   Evaluation of arterial stiffness and cardiac function in patients with vascular erectile dysfunction: acute effects of phosphodiesterase-5 inhibitor tadalafil [J].
O Özdabakoğlu ;
S Güllülü ;
S Sağ ;
T Şentürk ;
H Kiliçarslan ;
A Tütüncü ;
M Keçebaş ;
İ Baran ;
A Aydinlar .
International Journal of Impotence Research, 2017, 29 :96-100
[46]   EFFECTS OF PHOSPHODIESTERASE-5 INHIBITOR TADALAFIL ON TRANSIENT CEREBRAL ISCHEMIA IN GERBILS: IMPLICATIONS FOR A NEW TREATMENT STRATEGY [J].
Park, H. J. ;
Lee, H. S. ;
Cho, Y. S. ;
Joo, K. J. ;
Kwon, C. H. ;
Kim, K. H. .
JOURNAL OF SEXUAL MEDICINE, 2012, 9 :267-267
[47]   The phosphodiesterase-5 inhibitor tadalafil decreases ET-1 expression in HUVECs and suppresses circulating ET-1 levels type 2 diabetes mellitus patients [J].
Olausson, J. ;
Sjogren, L. ;
Hulten, L. Mattsson ;
Jansson, P. A. .
DIABETOLOGIA, 2013, 56 :S519-S520
[48]   Effects of the Phosphodiesterase Type 5 Inhibitor Tadalafil on Morphine Analgesia and Tolerance in Rats [J].
Taskiran, Ahmet Sevki ;
Ozdemir, Ercan ;
Arslan, Gokhan .
ACTA PHYSIOLOGICA, 2017, 221 :82-83
[49]   Phosphodiesterase-5 (PDE-5) inhibitor use in middle-aged and older men with erectile dysfunction: Results from the Massachusetts Male Aging Study [J].
O'Donnell, AB ;
Araujo, AB ;
Hatzichristou, D ;
McKinlay, JB .
JOURNAL OF UROLOGY, 2006, 175 (04) :325-325
[50]   Effects of the Phosphodiesterase-5 (PDE-5) Inhibitors, Avanafil and Zaprinast, on Bone Remodeling and Oxidative Damage in a Rat Model of Glucocorticoid-Induced Osteoporosis [J].
Huyut, Zubeyir ;
Bakan, Nuri ;
Yildirim, Serkan ;
Alp, Hamit Hakan .
MEDICAL SCIENCE MONITOR BASIC RESEARCH, 2018, 24 :47-58
12345